loading...| Preferred Name | Dactinomycin | |
| Synonyms |
dactinomycin Actinomycin-[thr-val-pro-sar-meval] Lyovac cosmegen Actinomycin D Actinomycin I1 ACTINOMYCIN D Actinomycin C1 Actinomycin IV DACTINOMYCIN Lyovac Cosmegen Actinomycin A IV Dactinomycin Dactinomycine Meractinomycin Actinomycin X 1 2-bis[Cyclo(N-methyl-L-valyl-sarcosyl-L-prolyl-D-valyl-L-threonyl)]-1,9 dimethyl-4,6 3H-phenoxazinone-3 Cosmegen DACT |
|
| Definitions |
A chromopeptide antineoplastic antibiotic isolated from the bacterium Streptomyces parvulus. Dactinomycin intercalates between adjacent guanine-cytosine base pairs, blocking the transcription of DNA by RNA polymerase; it also causes single-strand DNA breaks, possibly via a free-radical intermediate or an interaction with topoisomerase II. (NCI04) |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C412 |
|
| Accepted_Therapeutic_Use_For |
Wilms' tumor; rhabdomyosarcoma; Ewing's sarcoma; testicular cancer; gestational trophoblastic neoplasia; choriocarcinoma; melanoma; neuroblastoma; retinoblastoma; uterine sarcomas; Kaposi's sarcoma; sarcoma botryoides; soft tissue sarcoma. |
|
| ALT_DEFINITION |
An anticancer drug that is a type of antitumor antibiotic. |
|
| alternative_term |
dactinomycin Actinomycin-[thr-val-pro-sar-meval] Lyovac cosmegen Actinomycin D Actinomycin I1 ACTINOMYCIN D Actinomycin C1 Actinomycin IV DACTINOMYCIN Lyovac Cosmegen Actinomycin A IV Dactinomycin Dactinomycine Meractinomycin Actinomycin X 1 2-bis[Cyclo(N-methyl-L-valyl-sarcosyl-L-prolyl-D-valyl-L-threonyl)]-1,9 dimethyl-4,6 3H-phenoxazinone-3 Cosmegen DACT |
|
| CAS_Registry |
50-76-0 |
|
| CHEBI_ID |
CHEBI:27666 |
|
| Chemical_Formula |
C62H86N12O16 |
|
| code |
C412 |
|
| Contributing_Source |
CTRP FDA |
|
| definition |
A chromopeptide antineoplastic antibiotic isolated from the bacterium Streptomyces parvulus. Dactinomycin intercalates between adjacent guanine-cytosine base pairs, blocking the transcription of DNA by RNA polymerase; it also causes single-strand DNA breaks, possibly via a free-radical intermediate or an interaction with topoisomerase II. (NCI04) |
|
| Display_Name |
Dactinomycin |
|
| FDA_UNII_Code |
1CC1JFE158 |
|
| fromPubMed |
true |
|
| imported from | ||
| in_subset |
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977 http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978 http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923 http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711 |
|
| label |
Dactinomycin |
|
| Legacy_Concept_Name |
Dactinomycin |
|
| NSC_Code |
3053 |
|
| oboInOwl:hasDbXRef | ||
| PDQ_Closed_Trial_Search_ID |
39675 |
|
| PDQ_Open_Trial_Search_ID |
39675 |
|
| preferred label |
Dactinomycin |
|
| Preferred_Name |
Dactinomycin |
|
| prefixIRI |
NCIT:C412 |
|
| prefLabel |
Dactinomycin |
|
| Semantic_Type |
Amino Acid, Peptide, or Protein Antibiotic |
|
| textual definition |
A chromopeptide antineoplastic antibiotic isolated from the bacterium Streptomyces parvulus. Dactinomycin intercalates between adjacent guanine-cytosine base pairs, blocking the transcription of DNA by RNA polymerase; it also causes single-strand DNA breaks, possibly via a free-radical intermediate or an interaction with topoisomerase II. (NCI04) |
|
| UMLS_CUI |
C0010934 |
|
| subClassOf |